Ligand Pharmaceuticals Incorporated (LGND)
Debt-to-capital ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 830,439 | 841,178 | 775,198 | 806,521 | 700,913 | 665,402 | 664,892 | 646,317 | 597,485 | 816 | 802,365 | 793,192 | 821,629 | 812,066 | 786,517 | 745,840 | 709,525 | 697,824 | 695,003 | 661,896 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $830,439K)
= 0.00
The debt-to-capital ratio for Ligand Pharmaceuticals Incorporated has consistently been 0.00 for the periods from March 31, 2020, to December 31, 2024. A debt-to-capital ratio of 0.00 indicates that the company has not used any debt to finance its operations relative to its total capital structure. This may suggest that the company has been relying more on equity financing or internal funds rather than debt to support its growth and operations. A low debt-to-capital ratio can also indicate a conservative financial strategy focused on minimizing financial risk and maintaining a strong balance sheet. Overall, the consistent 0.00 debt-to-capital ratio reflects a relatively low level of financial leverage and debt risk for Ligand Pharmaceuticals Incorporated.
Peer comparison
Dec 31, 2024